AstraZeneca

EsoBiotec is a Belgian biotechnology company dedicated to the discovery of innovative cancer therapies. The firm specializes in immunotherapies that aim to empower the human body to combat cancer through in vivo cell engineering. EsoBiotec focuses on developing cost-effective drugs and therapeutics, ensuring that patients have access to essential cancer treatments at lower costs. By prioritizing accessibility, the company seeks to improve the overall effectiveness of cancer care and enhance patient outcomes.

FibroGen China is committed to providing access to revolutionary medical treatment for patients.

Syneron was founded by Sinovation Ventures and is dedicated to using artificial intelligence and biotechnology to address two significant global challenges: the efficient development of novel biological therapies and the low-carbon manufacture of biochemicals.

Huma is a global health technology company that specializes in creating a modular platform for digital 'hospitals at home' across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting information from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time insights. The company focuses on advancing connected care for patients and accelerating research and therapy development. It collaborates with leading healthcare institutions to assess and improve health outcomes, empowering healthcare professionals to utilize data effectively for better patient care.

Nucleus RadioPharma is a company focused on enhancing the accessibility of radiopharmaceuticals for cancer patients. It specializes in developing innovative technologies aimed at modernizing the clinical development, manufacturing, and supply chain processes associated with radiopharmaceutical therapies. By streamlining these aspects, Nucleus RadioPharma seeks to improve the delivery of novel treatments, thereby enabling healthcare professionals to more effectively diagnose and treat various cancer diseases.

SixPeaks Bio is focused on developing innovative therapies aimed at promoting healthy weight loss for patients suffering from obesity. The company is creating a pipeline of medicines that utilize dual-specific antibodies targeting activin type IIA and B receptors. This approach is designed to effectively preserve skeletal muscle mass while facilitating reductions in body fat, addressing a critical aspect of weight loss that often leads to muscle loss. Through its specialized platform, SixPeaks Bio aims to provide effective treatment options that support sustainable weight management and improve overall health outcomes for individuals dealing with obesity.

SixPeaks Bio is focused on developing innovative therapies aimed at promoting healthy weight loss for patients suffering from obesity. The company is creating a pipeline of medicines that utilize dual-specific antibodies targeting activin type IIA and B receptors. This approach is designed to effectively preserve skeletal muscle mass while facilitating reductions in body fat, addressing a critical aspect of weight loss that often leads to muscle loss. Through its specialized platform, SixPeaks Bio aims to provide effective treatment options that support sustainable weight management and improve overall health outcomes for individuals dealing with obesity.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Nabla Bio is a biotechnology company that specializes in the development of an autoreverse platform for the discovery of innovative protein variants. These proteins, which exhibit unique qualities, are engineered to create new medicines and enhance nutritional products. By leveraging insights gained from billions of natural proteins, Nabla Bio enhances these variants through extensive experimentation, allowing for advanced applications in both medical and industrial fields. The company's focus on complex measurements of protein function positions it as a leader in the pursuit of previously unattainable protein capabilities.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines utilizing its proprietary virus-like particle (VLP) platform technology. This innovative approach allows for the multivalent, particle-based display of complex viral antigens, which is aimed at generating broad and durable immune responses. Icosavax focuses primarily on life-threatening respiratory diseases, with its lead vaccine candidate, IVX-121, targeting respiratory syncytial virus (RSV) in older adults. The company's pipeline also includes candidates for human metapneumovirus (hMPV) and SARS-CoV-2, reflecting its commitment to advancing vaccine solutions for infectious diseases.

Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.

Cullgen Inc. is a biopharmaceutical company based in San Diego, California, founded in 2018. The company specializes in the development of innovative small molecule therapeutics aimed at treating diseases that currently lack effective therapeutic options, including cancer, inflammatory, and autoimmune diseases. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins, even those previously deemed undruggable. This approach enables the creation of first-in-class new chemical entities, providing scientists with novel methodologies for drug discovery and potentially transforming treatment paradigms for difficult-to-treat conditions.

Promise Bio is a biotechnology company specializing in precision medicine for autoimmune diseases. It leverages epiproteomic analysis, a cutting-edge technique that examines protein modifications, using a cloud-based AI platform to interpret standard mass-spectrometry data. This innovative approach aims to uncover disease mechanisms and facilitate personalized treatment plans, ultimately improving patient care and affordability.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

GenAssist Therapeutics, founded in July 2020 by a team of leading scientists and industry experts, specializes in the development of gene therapy drugs utilizing advanced base editing technology. The company is focused on addressing neuromuscular diseases that currently lack effective treatments, particularly Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). GenAssist aims to provide permanent cures by precisely repairing disease-causing genes directly within patients' cells. The company holds global intellectual property rights to its proprietary Targeted AID-based Mutagenesis (TAM) technology, positioning it at the forefront of innovative solutions for a range of genetic disorders.

Neogene Therapeutics, Inc., founded in 2018 and based in New York, develops innovative T cell therapies aimed at treating cancer. The company specializes in creating personalized engineered T cells that target mutated proteins, known as neo-antigens, found in cancer cells as a result of DNA mutations. By leveraging advanced technologies, Neogene isolates neo-antigen specific T cell receptor genes from tumor biopsies, which are routinely collected during cancer treatment. These tumor-infiltrating lymphocytes often express T cell receptors that can recognize and attack cancer cells displaying neo-antigens. Utilizing state-of-the-art DNA sequencing, synthesis, and genetic screening, Neogene's proprietary platform enables the identification of these specific T cell receptors with high sensitivity and at scale, ultimately enhancing the efficacy of cancer treatments.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

ZSHK Lab is a company located in Wan Chai, Hong Kong Island, Hong Kong.

Yunjian is a new generation of metabolomics- and protein-based marker-finding technologies. has developed a distinctive analytic platform based on mass spectrometry proteomics and big data, driven by medical theories that greatly reduce the time required by conventional methods to find disease markers. has a wealth of experience in big data illness models, medication development, disease biomarker identification, clinical translation and diagnostics, and data security.

Doctor.One is a next-generation virtual clinic that enables physicians to establish and manage subscription-based private practices. The company's platform facilitates direct communication between doctors and patients, allowing physicians to respond to messages, monitor treatment progress, and provide assistance through asynchronous chat. Additionally, the platform supports video consultations without requiring the disclosure of personal phone numbers and enables doctors to issue prescriptions. By focusing on direct access to healthcare professionals, Doctor.One aims to restore the trusted doctor-patient relationship, creating a foundation for improved healthcare delivery.

TeneoTwo is a biotechnology firm that develops potential new medicine for B-cell haematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma.

Axbio Inc. is a biotechnology company based in Shenzhen, China, focused on developing and manufacturing advanced technology for genetic sequencing and molecular diagnostics. Founded in 2016, Axbio produces a variety of genome extraction kits for different sample types, including stool, blood, saliva, and bacteria. The company's offerings also include sequencing and diagnostic systems, disposable biochips, and reagents. Axbio's innovative platform utilizes semiconductor nanotechnology and microfluidics, allowing for high-throughput sequencing and diagnostics. This technology supports a range of applications, from low-cost handheld devices for bedside diagnostics to fully automated laboratory instruments, facilitating services such as early cancer screening, rapid pathogen detection, and drug development. Currently, Axbio is operating in stealth mode as it continues to enhance its product offerings and industrial solutions.

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

Huma is a global health technology company that specializes in creating a modular platform for digital 'hospitals at home' across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting information from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time insights. The company focuses on advancing connected care for patients and accelerating research and therapy development. It collaborates with leading healthcare institutions to assess and improve health outcomes, empowering healthcare professionals to utilize data effectively for better patient care.

Creativity (Beijing) Medical Technology Development Co., Ltd. is a leading minimally invasive interventional delivery system product full solution provider. Committed to cooperating with top experts at home and abroad in the field of minimally invasive intervention, and cooperating with internationally renowned raw material manufacturers to jointly develop, produce and sell leading products. Provide doctors with differentiated diagnosis and treatment tools, relieve patients' pain and reduce medical burden.

Caelum Biosciences, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare and life-threatening diseases. The company’s lead product, CAEL-101, is a novel antibody licensed from Columbia University, specifically designed to treat amyloid light chain amyloidosis, a serious condition that can result in organ failure and death. Clinical data presented at various medical conferences indicate that CAEL-101 has the potential to be a safe and well-tolerated therapy that promotes amyloid resolution, with evidence suggesting a correlation between reduced levels of N-terminal pro-brain natriuretic peptide and improved cardiac function in patients with cardiac AL amyloidosis. The U.S. Food and Drug Administration has granted CAEL-101 Orphan Drug Designation as both a therapeutic agent and a radio-imaging agent for amyloidosis. In January 2019, Caelum entered into a collaboration agreement with Alexion Pharmaceuticals to further the development of CAEL-101, which includes a financial commitment of $60 million from Alexion.

Cellular Biomedicine Group, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company employs proprietary cell-based technologies, including various forms of CAR-T therapy, which targets different cancer types, and human adipose-derived mesenchymal progenitor cells aimed at treating joint diseases. Its product pipeline features therapies such as CD20 and CD22 CAR-T for B cell malignancies, and alpha fetoprotein TCR-T targeting hepatocellular carcinoma. Additionally, Cellular Biomedicine is developing knee osteoarthritis treatments, including AlloJoin and Re-Join, the latter having completed Phase IIb trials. The company also engages in broader biopharmaceutical activities, encompassing research and development, technical support, and manufacturing of pharmaceutical polypeptides and medical devices. It has established a partnership with Novartis Pharma AG to produce and supply the CAR-T cell therapy Kymriah in China. Founded in 2001, Cellular Biomedicine Group is headquartered in New York, New York, and draws on a wealth of cellular medicine research and expertise from scientists and clinicians across the United States, England, and China.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

OnDosis is a Swedish company founded in 2017, focusing on personalized medicine through its innovative dosing technology. The company specializes in delivering flexible and individualized dosing of oral medications, which are formulated as micro units like pellets, granules, mini tablets, or powders. By integrating digital technologies with traditional drug-based treatments, OnDosis aims to enhance disease management and improve patient adherence, particularly for conditions such as ADHD, pain management, and immunosuppression in organ transplant recipients. Their approach addresses the limitations of conventional tablets or capsules, providing greater convenience and improved health outcomes for patients. The technology developed by OnDosis is rooted in research from AstraZeneca and is supported by a network of strategic partners that assist in various core functions, including formulation, device development, and regulatory compliance.

ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company's lead product candidates include ADCT-402, currently undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, which is in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. ADC Therapeutics employs advanced pyrrolobenzodiazepine (PBD) dimer technology to create highly potent and targeted ADCs, which demonstrate a superior therapeutic index compared to earlier generation products. In addition to its lead candidates, the company is developing several clinical-stage and preclinical product candidates, including ADCT-601, ADCT-602, ADCT-701, and ADCT-901. ADC Therapeutics also collaborates with Genmab A/S to enhance its development efforts. The company was incorporated in 2011.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in first-in-class immunotherapy drug candidates that target receptors and pathways controlling innate immunity. Its product pipeline includes Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell lymphoma. Other notable candidates include IPH5201, a CD39-targeting antibody in Phase I trials, and IPH5301, a CD73-blocking antibody in preclinical development. Innate Pharma utilizes its proprietary ANKET platform to create innovative therapies and has established licensing and collaboration agreements with major pharmaceutical companies. Founded in 1999, Innate Pharma continues to advance its mission of harnessing the innate immune system to improve cancer treatment outcomes.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, which is expressed on various immune system B cells. This candidate is being developed for multiple indications, including neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. Additionally, Viela Bio is advancing VIB4920, aimed at preventing kidney transplant rejection and treating sjögren’s syndrome, as well as VIB7734, which targets cutaneous lupus erythematosus. The company has established a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several Asian markets. Founded in 2017, Viela Bio aims to address critical pathways underlying these diseases and improve patient outcomes globally.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company focused on developing oral delivery systems for large drug molecules, including peptides, proteins, and antibodies. The company has created the RaniPill capsule, a novel and patented technology designed to replace traditional subcutaneous or intravenous injections with an oral dosing method. This capsule is engineered to automatically release a precise therapeutic dose of medication in the small intestine, aiming to enhance patient compliance and comfort. Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill, contributing to a robust intellectual property portfolio. The company's therapeutic offerings include treatments for inflammatory disorders, osteoporosis, growth deficiencies, and multiple sclerosis, among others. Founded in 2012 and based in San Jose, California, Rani Therapeutics seeks to improve patient outcomes by providing a convenient alternative to painful injections.

ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company's lead product candidates include ADCT-402, currently undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, which is in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. ADC Therapeutics employs advanced pyrrolobenzodiazepine (PBD) dimer technology to create highly potent and targeted ADCs, which demonstrate a superior therapeutic index compared to earlier generation products. In addition to its lead candidates, the company is developing several clinical-stage and preclinical product candidates, including ADCT-601, ADCT-602, ADCT-701, and ADCT-901. ADC Therapeutics also collaborates with Genmab A/S to enhance its development efforts. The company was incorporated in 2011.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company focused on developing oral delivery systems for large drug molecules, including peptides, proteins, and antibodies. The company has created the RaniPill capsule, a novel and patented technology designed to replace traditional subcutaneous or intravenous injections with an oral dosing method. This capsule is engineered to automatically release a precise therapeutic dose of medication in the small intestine, aiming to enhance patient compliance and comfort. Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill, contributing to a robust intellectual property portfolio. The company's therapeutic offerings include treatments for inflammatory disorders, osteoporosis, growth deficiencies, and multiple sclerosis, among others. Founded in 2012 and based in San Jose, California, Rani Therapeutics seeks to improve patient outcomes by providing a convenient alternative to painful injections.

Ethris GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative therapeutic solutions for diseases with unmet medical needs. The company has a focus on transcript therapeutics, particularly through its SNIM RNA platform, which offers a novel approach to treating various conditions by enabling the production of therapeutic proteins within the patient’s body. This platform presents an alternative to traditional recombinant protein and gene therapies, addressing a range of diseases, including rare and genetically predetermined conditions. Ethris also develops Magnetovax, a personalized tumor vaccine platform that utilizes magnetic fields for localized activation in tumors. The company has established strategic research collaborations with major pharmaceutical firms, enhancing its capabilities in regenerative medicine and therapeutic development. Founded in 2009, Ethris continues to advance its technologies to meet diverse medical needs.

ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company's lead product candidates include ADCT-402, currently undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, which is in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. ADC Therapeutics employs advanced pyrrolobenzodiazepine (PBD) dimer technology to create highly potent and targeted ADCs, which demonstrate a superior therapeutic index compared to earlier generation products. In addition to its lead candidates, the company is developing several clinical-stage and preclinical product candidates, including ADCT-601, ADCT-602, ADCT-701, and ADCT-901. ADC Therapeutics also collaborates with Genmab A/S to enhance its development efforts. The company was incorporated in 2011.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

FibroGen, Inc. is a biopharmaceutical company based in San Francisco, California, dedicated to discovering, developing, and commercializing therapeutics aimed at addressing serious unmet medical needs. The company is advancing Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylases, which is in Phase III clinical development for treating anemia related to chronic kidney disease in the United States and Europe, and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. Additionally, FibroGen is developing Pamrevlumab, a human monoclonal antibody that inhibits connective tissue growth factor activity, currently in Phase III trials for idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as undergoing Phase II trials for Duchenne muscular dystrophy. The company collaborates with partners such as Astellas Pharma Inc. and AstraZeneca AB to enhance its research and development efforts. Founded in 1993, FibroGen continues to leverage its expertise in HIF and CTGF biology to innovate in the fields of anemia, fibrotic diseases, and cancer.

Takeda defined four therapeutic areas of focus: Gastroenterology, Oncology, Central Nervous System, and Cardiovascular and Metabolic.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company focused on developing oral delivery systems for large drug molecules, including peptides, proteins, and antibodies. The company has created the RaniPill capsule, a novel and patented technology designed to replace traditional subcutaneous or intravenous injections with an oral dosing method. This capsule is engineered to automatically release a precise therapeutic dose of medication in the small intestine, aiming to enhance patient compliance and comfort. Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill, contributing to a robust intellectual property portfolio. The company's therapeutic offerings include treatments for inflammatory disorders, osteoporosis, growth deficiencies, and multiple sclerosis, among others. Founded in 2012 and based in San Jose, California, Rani Therapeutics seeks to improve patient outcomes by providing a convenient alternative to painful injections.

Acerta Pharma is focused on the development of covalent binding technology solutions to create therapies for cancer. Acerta Pharma was acquired by AstraZeneca in February 2016. Acerta Pharma was founded in 2013 and is based in San Carlos, California.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, specializing in the development and commercialization of non-absorbed drugs aimed at treating renal, cardiovascular, liver, and metabolic diseases. Founded in 2008, the company focuses on creating highly selective ion-trap therapies using its proprietary zirconium silicate technology, which allows for the reduction of toxic electrolyte levels while maintaining overall electrolyte balance. Its lead product, ZS-9, is an insoluble, non-absorbed zirconium silicate currently in Phase III clinical trials for the treatment of hyperkalemia, a serious condition characterized by elevated potassium levels in the blood, often affecting patients with chronic kidney disease, hypertension, diabetes, or heart failure. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company's lead product candidates include ADCT-402, currently undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, which is in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. ADC Therapeutics employs advanced pyrrolobenzodiazepine (PBD) dimer technology to create highly potent and targeted ADCs, which demonstrate a superior therapeutic index compared to earlier generation products. In addition to its lead candidates, the company is developing several clinical-stage and preclinical product candidates, including ADCT-601, ADCT-602, ADCT-701, and ADCT-901. ADC Therapeutics also collaborates with Genmab A/S to enhance its development efforts. The company was incorporated in 2011.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

MdBio Foundation, Inc. has been providing innovative and effective bioscience education for middle and high school students since 1997. The non-profit, (501 c 3) organization is dedicated to providing bioscience awareness, education, and workforce development in the state of Maryland and beyond. The Foundation accomplishes this through a diverse set of programs, including their flagship program, MdBioLab, summer programs, and their leading-edge game-based learning platform, MdBioSphere. MdBio Foundation leverages its established, trusted relationships with private industry and school systems to create authentic, STEM-based career experiences on their mobile laboratory, MdBioLab, and through their youth camp, the Young Science Explorers Program (YSEP). These experiences provide a unique opportunity for students to observe first hand the types of careers they could pursue in STEM-related fields. Students and teachers who participate in MdBioLab and YSEP have increased access to information about bioscience industry products, research, and related careers through problem-based laboratory experiences that are aligned with local, state and, national curriculum standards. Commitment to Excellence: Since its inception, The MdBio Foundation has contributed more than $3.5M of their resources to these programs and will continue to invest more than $500K each year. The Foundation’s staff consists of talented and experienced educators and scientists who share a common goal of improving science education and creating a more accessible, educational experience.

Almirall is an international pharmaceutical company based in Barcelona, Spain, focused on innovation and dedicated to improving health and wellbeing. The company engages in the research, development, manufacture, and marketing of medicinal products across various therapeutic areas, including dermatology, respiratory, gastrointestinal, and central nervous system disorders. Almirall operates through multiple segments, including sales through its own network, licensed products, and research and development initiatives. Its medical dermatology business in Europe is a primary driver of its operations, while the company also extends its presence to the Americas, Asia, Africa, and Oceania through subsidiaries.

Ashland-Boyd County Health Department is a public health service provider based in Boyd County, Kentucky. Established with a mission to enhance the quality of life for residents, it offers disease prevention programs, health promotion initiatives, environmental safety measures, and public health preparedness services. The department focuses on supporting pregnant women, postpartum mothers, breastfeeding individuals, and infants up to one year old by providing nutrition education, counseling, breastfeeding information, nutritious foods, and assistance in accessing healthcare services during critical growth stages.

UnityPoint Health is a prominent nonprofit health system in the United States, established in 1993. It operates an integrated network that includes over 280 physician clinics, 30 hospitals, and home care services across eight regions in Iowa and Illinois. The organization prioritizes effective communication among its physician-led teams to ensure patients receive appropriate care in clinics, hospitals, or at home. Annually, UnityPoint Health facilitates more than 4 million patient visits, delivering a comprehensive range of coordinated healthcare services to individuals and families. With annual revenues of $2.7 billion, it ranks as the 13th largest nonprofit health system in the nation and the fourth largest nondenominational health system.

Elkhorn Logan Valley Public Health Department was created in 2002 to serve the citizens and communities of Burt, Cuming, Madison and Stanton counties. Located in Wisner, Nebraska, with a satellite office in Norfolk, the department focuses on healthy lifestyle management and disease prevention with over 20 programs initiated to maximize wellness and safety.

North Georgia Healthcare Center is a non-profit health care center in Ringgold, Georgia. NGHCC is federally funded by the U.S.D.A. Direct Loan Program funds. The organization will seek sponsorship through private corporations, community, and grants and it will accept Private Insurance, Medicare, Medicaid. NGHCC will offer medical services to North Georgia and surrounding areas seven days a week with extended hours.

Established in 1996, Catherine’s Health Center is a 501(c)(3) safety net medical clinic, serving more than 6,000 patients annually. Using a small core of paid staff and many dedicated volunteers, Catherine’s mission is to provide free or low-cost medical services to low-income, uninsured and underinsured residents of Kent Count.Catherine’s Health Center is a non-profit community-based health facility dedicated to serving low-income, uninsured residents of the northeast sections of Grand Rapids, Michigan, primarily those who live in the Creston and Belknap neighborhoods. Supporting the center’s activities are a governing board and group of volunteers working to make health care available to those in need.

Allegiance Health is a community-owned, locally-governed health system in Jackson, Michigan. We combine hospital-based care with a full range of services for all members of our community. Allegiance is a leader in forming community partnerships which innovatively address wellness and preventative needs. We are proudly entering our 10th decade of serving the people of south central Michigan with local, high-quality care.Comprised of more than 40 different facilities, Allegiance reaches the residents of Jackson, Hillsdale, Lenawee, Ingham, Calhoun and Washtenaw counties and beyond. Wherever we are in the region, our mission remains constant. We lead our community to better health and well-being at every stage of life. Our vision is to create Michigan’s healthiest community through exceptional health care and inspiring a passion for wellness.

Matthew Walker Comprehensive Health Center, Inc. provides healthcare and health education services. It provides pediatric care, family and internal medicine, general dentistry, ophthalmology, geriatrics, obstetrics and gynecology, nutrition, mental health, pharmacy, radiology, and diagnostic laboratory testing and screening services. The company was founded in 1968 and is based in Nashville, Tennessee.

The Health Wagon is a nonprofit organization providing mobile health services to the medically underserved in southwest Virginia. The Health Wagon’s mission is to provide compassionate, quality healthcare to the medically underserved in the mountains of Appalachia. The Health Wagon visits 10 sites in six counties – Buchanan, Dickenson, Lee, Russell, Scott, and Wise counties – to serve a severely medically underserved population. The Health Wagon currently has two mobile health units and two stationary clinics servicing southwest Virginia.

Whittier Street Health Center (WSHC) is a comprehensive, innovative and high quality health care and wellness center championing equitable access to high quality, cost-effective health care for diverse populations. WSHC is accredited by The Joint Commission (TJC), certified by the NCQA as a golden level (highest ranking) patient centered medical home and licensed by the Massachusetts Department of Public Health (DPH). The vision of the Whittier Street Health Center is to serve as the premiere health center for Boston residents and the mission is to provide high quality, reliable and accessible primary care and support services to promote wellness and eliminate health and social disparities. Located in the Roxbury neighborhood of Boston, Whittier Street Health Center provides comprehensive health services including primary care, behavioral health care, substance abuse services, dental care and eye care to over 25,000 patients. A trusted member of the community for 80 years, Whittier is here to provide the care that you and your family need to get healthy and stay healthy. We provide many services to help raise it out of poverty and into a place of good health. Having translators for 17 languages and utilizing clinical and social services to meet specific community needs through outreach, targeted programs and state of the art health care delivery helps us stay connected with the community.

UCHealth Pikes Peak Regional Hospital is a not-for-profit medical facility located in Woodland Park, Colorado, dedicated to enhancing individual and community health. The hospital aims to improve lives through a combination of innovative, academic-based medicine and a strong focus on community care. By offering evidence-based health care and wellness services, UCHealth strives to deliver comprehensive, high-quality medical care that meets the diverse needs of its patients. The hospital is part of a broader network that includes various clinics and outpatient services across northern Colorado, Nebraska, and Wyoming, emphasizing its commitment to serving a wide geographic area. With a mission centered on human connection and personal care, UCHealth Pikes Peak Regional Hospital plays a vital role in the health and well-being of the communities it serves.

Sankofa Community Development Corporation, established in 2008, is a nonprofit organization dedicated to revitalizing the Lower and Upper Ninth Ward communities of New Orleans. The organization focuses on urban revitalization by promoting healthy living, youth empowerment, and intergenerational learning. Sankofa offers various initiatives, including the Sankofa Mobile Market, which provides access to healthy food options, and the Sankofa HEAL Project, aimed at enhancing community well-being. Additionally, the Sankofa Learning Gardens and Farms Project supports educational opportunities and employment for youth, fostering a healthier environment and contributing to the overall stability and viability of lower middle-class neighborhoods in the area. Through these efforts, Sankofa Community Development plays a crucial role in enhancing the quality of life for residents while addressing the challenges faced by the community.

Dr. Arenia C. Mallory Community Health Center (MCHC) is named to honor the memory of Dr. Arenia C. Mallory, well known educator and champion of human causes. She inspired young minds regardless of their race, economic or social status to “Walk in Dignity, Talk in Dignity, and Live in Dignity”.

Manna Ministries has a longstanding commitment to fiscal responsibility and is audited each year by an independent CPA firm. Our audits reveal that 96% of our funding goes directly to support our programs, while only 4% goes to administrative costs. Partnerships allows us to help more people lead healthier lives by providing them with the basic necessities of life such as food, shelter, and healthcare.

The Food Trust, a nonprofit founded in 1992, strives to make healthy food available to all. Working with neighborhoods, schools, grocers, farmers and policymakers, we've developed a comprehensive approach that combines nutrition education and greater availability of affordable, healthy food.

Christiana Care Health System, located in Wilmington, DE, is one of the largest healthcare providers in the mid-Atlantic region, serving Delaware and parts of Pennsylvania, Maryland, and New Jersey. As a not-for-profit teaching health system, it operates two hospitals with over 1,100 patient beds, alongside a comprehensive array of services including home health care, preventive medicine, and rehabilitation. The organization also maintains a robust network of primary care physicians and extensive outpatient services. Christiana Care is recognized for its excellence in various specialties, including cardiology, cancer treatment, orthopaedics, and women's health, as well as for its advanced Level-I trauma care and Level-3 neonatal intensive care capabilities.

Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California, with additional operations in Huntsville, Alabama, and Hyderabad, India. The company focuses on researching and developing investigational drugs for oncology, immunology, and virology, alongside a portfolio of partnered approved medicines. Its clinical pipeline includes notable candidates such as NKTR-181 for chronic low back pain, ONZEALD for advanced metastatic breast cancer, and Bempegaldesleukin, designed to enhance cancer-killing T cell activity. Nektar is also developing therapies for autoimmune diseases, including NKTR-358, and various other conditions like hemophilia A, opioid-induced constipation, and systemic lupus erythematosus. The company's strategy involves leveraging the immune system to combat cancer and restore immune balance in autoimmune disorders. Nektar has established collaboration agreements with several major pharmaceutical companies, enhancing its research capabilities and development efforts. Incorporated in 1990, Nektar Therapeutics continues to advance its innovative drug candidates through various stages of clinical trials.

Pearl Therapeutics is a private company focused on developing advanced inhaled therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, asthma, and rhinosinusitis. The company specializes in creating unique dual and triple combination products that aim to improve the safety and efficacy of existing respiratory treatments. Led by a team of experts in respiratory product development, Pearl Therapeutics seeks to provide patients and healthcare providers with effective alternatives that enhance clinical outcomes. By utilizing familiar metered dose inhalers, Pearl endeavors to make its innovative therapies accessible to a broad patient population.

Omthera Pharmaceuticals, Inc. is a specialty pharmaceuticals company that specializes in the clinical development of innovative therapies for dyslipidemia, a condition characterized by elevated triglyceride levels and an increased risk of cardiovascular disease. The company is led by a team of seasoned experts in the field of lipid disorders, committed to creating effective treatments aimed at improving patient outcomes. By focusing on the needs of the millions affected by dyslipidemia, Omthera strives to advance healthcare solutions that address this significant health challenge.

Ardea Biosciences, based in San Diego, California, is a biotechnology company dedicated to developing small-molecule therapeutics aimed at treating serious diseases. The company's primary focus is on its lead product candidate, RDEA594, which is a selective URAT1 transporter inhibitor currently in Phase 2 clinical development for the treatment of hyperuricemia and gout. Through its innovative approach to drug development, Ardea aims to address unmet medical needs in these conditions.

Guangdong BeiKang Pharmaceutical Company Ltd manufactures drugs which includes generic injectable antibiotics.

Novexel is a pharmaceutical company dedicated to the research and development of innovative anti-infective therapies for severe bacterial and fungal infections. The company has a robust portfolio of antibacterial and anti-fungal compounds, along with comprehensive R&D programs and intellectual property. Novexel specializes in creating novel antimicrobial agents that target multi-resistant organisms, addressing the growing challenge of microbial resistance. With expertise in biology, medicinal chemistry, pharmacology, microbiology, and clinical development, Novexel is positioned to lead advancements in the discovery and development of effective treatments for infectious diseases.

MedImmune, established in 1988, is a global biopharmaceutical company and the biologics R&D arm of AstraZeneca. It specializes in developing medicines for unmet medical needs, focusing on therapeutic areas such as respiratory, inflammation, autoimmunity, cardiovascular and metabolic disease, oncology, neuroscience, and infection and vaccines. MedImmune Ventures, its venture capital arm founded in 2002, invests in early to late-stage, public and private biotechnology companies globally, with an average investment of $7 million. The firm seeks to invest in companies developing small and large molecule therapeutics, vaccines, pharmaceutical technologies, and platforms, as well as medical devices, diagnostics, and healthcare information technology companies, supporting the discovery, development, and commercialization of pharmaceutical products.

Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England.

KuDOS Pharmaceuticals Ltd is a pharmaceutical research firm focused on discovering and developing innovative oncological drugs. The company specializes in the science of DNA damage sensing, signaling, and repair, aiming to address critical medical needs in cancer treatment. KuDOS develops small molecule drugs that selectively inhibit the repair processes in cancer cells, thereby enhancing their destruction and improving overall cancer management. This approach is designed to provide patients with better outcomes from radiotherapy and chemotherapeutic treatments, ultimately contributing to more effective cancer care.